Now showing items 1-2 of 2
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer
(Institute of Cancer Research (University Of London), 2019-12-31)
KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ...